Bio-Rad Laboratories (BIO) EBIT (2009 - 2026)

Bio-Rad Laboratories (BIO) has 18 years of EBIT data on file, last reported at $34.1 million in Q1 2026.

• On a quarterly basis, EBIT rose 43.88% year-over-year to $34.1 million in Q1 2026; TTM through Mar 2026 was $57.6 million, a 76.77% decrease from a year earlier, with the FY2025 full-year figure at $47.2 million, down 82.45% from the prior year.
• EBIT for Q1 2026 stood at $34.1 million, up from -$118.9 million in the prior quarter.
• Over the last five years, EBIT for BIO reached as high as $146.4 million in Q1 2022 and fell as low as -$118.9 million in Q4 2025.
• Historically, EBIT has averaged $68.9 million across 5 years, with a median of $77.1 million in 2025.
• Across the five-year window, EBIT jumped 45.16% in 2022 and sank 303.95% in 2025, its largest moves.
• Year by year, EBIT stood at $118.7 million in 2022, then declined by 19.66% to $95.3 million in 2023, then plunged by 38.84% to $58.3 million in 2024, then sank by 303.95% to -$118.9 million in 2025, then jumped by 128.68% to $34.1 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were $34.1 million in Q1 2026, -$118.9 million in Q4 2025, and $65.3 million in Q3 2025.